Issues relating to polymorphism can present a huge challenge to drug developers.  The cost and time spent to find and consistently produce a drug in a stable and optimal form, can severely impact on development programmes.  Encap can help reduce this risk.

By incorporating the API into a solution which is compatible with our capsule technologies, we can help to reduce the work required to overcome issues relating to the solid state of the API.  As well as reducing the amount of solid state work required we can help dramatically reduce the amounts of API required in early clinical evaluation.